IRF6

Across TCGA pan-cancer cohorts, IRF6 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated IRF6 data layer compared with 20 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher IRF6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IRF6 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

COAD, LUSC, and UCEC are the cancer types where IRF6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.125	0.799	<.001	21	view →
LUSC	OS	Median	IV	0.001	0.673	.014	12	view →
UCEC	DFS	Median	All	1.000	0.828	.014	12	view →
BLCA	DFS	Median	III,IV	1.000	0.269	.023	11	view →
TGCT	DFS	Median	All	0.151	0.801	.026	6	view →
SARC	OS	Median	All	0.205	0.826	<.001	6	view →
LUAD	OS	Median	II,III,IV	0.090	0.677	<.001	6	view →
SKCM	DFS	Median	All	0.058	0.757	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

IRF6–COAD (OS)

Open the COAD breakdown →